Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients

International Journal of Fertility and Sterility

Volumn 3, Issue 1, 2009, Pages 35-40

  Sohrabvand, Farnaz ^a   Ansaripour, Soheila ^a   Bagheri, Maryam ^a   Shariat, Mamak ^a   Jafarabadi, Mina ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cabergoline; Coasting; Ovarian hyperstimulation syndrome; Prevention

Indexed keywords

BUSERELIN; CABERGOLINE; CHORIONIC GONADOTROPIN; ESTRADIOL; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; COASTING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION; HIGH RISK PATIENT; HUMAN; INFERTILITY THERAPY; INTERMETHOD COMPARISON; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METAPHASE; OOCYTE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PREGNANCY RATE; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 70449638233     PISSN: 2008076X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992; 58(2): 249-261.
2. Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril. 1991; 55(1): 220-221.
3. Mathur R, Jenkins J. Ovarian hyperstimulation syndrome: an endocrinopathy? Curr Opin Obstet Gynecol. 2001; 13(3): 329-333.
4. Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000 May;73(5):883-896
5. Delvigne A, Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod. 2001; 16(12): 2491-2495. (Pubitemid 34007461)
6. Egbase PE, Al-Sharhan M, Grudzinskas JG. 'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod. 2002; 17(5): 1212-1216.
7. Dhont M, Van der Straeten F, De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertil Steril. 1998; 70(5): 847-850. (Pubitemid 28499077)
8. Benadiva CA, Davis O, Kligman I, Moomjy M, Liu HC, Rosenwaks Z. Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril. 1997; 67(4): 724-727. (Pubitemid 27152383)
9. Sher G, Zouves C, Feinman M, Maassarani G. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod. 1995; 10(12): 3107-3109.
10. Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta AM. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod. 2005; 20(11): 3167-3172. Epub 2005; 8.
11. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology. 2002; 143(11): 4339-4348. (Pubitemid 35239566)
12. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/ vascular endothelial growth factor. Nat Med. 2001; 7(5): 569-574. (Pubitemid 32448324)
13. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006; 147(11): 5400-5411.
14. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007; 92(8): 2882-2884.
15. Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol. 2005; 122(1): 127-128.
16. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989; 44(6): 430-440.
17. Aboulghar MA, Mansour RT, Serour GI, Rhodes CA, Amin YM. Reduction of human menopausal gonadotropin dose before coasting prevents severe ovarian hyperstimulation syndrome with minimal cycle cancellation. J Assist Reprod Genet. 2000; 17(5): 298-301.
18. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod. 2002; 17(2): 310-313. (Pubitemid 34168432)
19. Egbase PE, Sharhan MA, Grudzinskas JG . Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod. 1999; 14(6): 1421-1425.
20. García-Velasco JA, Zúñiga A, Pacheco A, Gómez R, Simón C, Remohí J, et al. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod. 2004; 19(7): 1530-1538. (Pubitemid 38997176)
21. Ajonuma LC, Ajuonuma FO, Chukwu CL. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod. 2005; 20(2): 574-575.
22. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol. 2003 ; 46(2): 349-362.
23. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999; 84(7): 2518-2522. (Pubitemid 30670888)
24. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994; 331(14): 904-909.
25. Weil C. The safety of bromocriptine in long-term use: a review of the literature. Curr Med Res Opin. 1986; 10(1): 25-51. (Pubitemid 16145079)
26. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996; 10(4): 333-337. (Pubitemid 26310263)